1.
Augustin M, Wegtowska J, Lebwohl M, Paul C, Piguet V, Sofen H, Blauvelt A, Peterson L, al. E. Durability of Response in Patients with Chronic Plaque Psoriasis Treated with Certolizumab Pegol over 48 Weeks: Pooled Results from Ongoing Phase 3, Multicenter, Randomized, Placebo-Controlled Studies (CIMPASI-1, CIMPASI-2 and CIMPACT). J of Skin [Internet]. 2018Dec.17 [cited 2020Nov.26];20:S87. Available from: https://jofskin.org/index.php/skin/article/view/484